Regulation 30 the Securities and Exchange Board of India ( Listing Obligation and Disclosure Requirement ) Regulation, 2015.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Shukra Pharmaceuticals' board, at its meeting on November 29, 2025, approved the continuation of Mr. Jitendra Somchand Shah (DIN: 01609325) as a Non-Executive Independent Director. Mr. Shah turned 75 in September 2025, triggering the SEBI Regulation 17(1A) requirement for shareholder approval. He was originally appointed on July 10, 2024 and his current term runs until the conclusion of the 36th Annual General Meeting. The company will seek shareholder consent via a postal ballot. Mrs. Rupal Patel, a Practicing Company Secretary, has been appointed as the Scrutinizer for the postal ballot process. The board confirmed Mr. Shah is not debarred from holding office by any SEBI or other authority.
This is a routine governance compliance filing with no material impact on the stock. Shareholders will get to vote on the continuation of the director through postal ballot, but no change in leadership or business direction is involved.